Update on the treatment of juvenile idiopathic arthritis

Current Allergy and Asthma Reports

Volumn 13, Issue 4, 2013, Pages 337-346

  Harris, Julia G ^a   Kessler, Elizabeth A ^a   Verbsky, James W ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Antirheumatic agents; Biological agents; Glucocorticoids; Immunoconjugates; Immunosuppressive agents; Interleukin 1 receptor antagonist protein; Interleukin 1; Interleukin 6; Intra articular injections; Juvenile idiopathic arthritis; Methotrexate; Monoclonal antibodies; Non steroidal anti inflammatory agents; Recombinant fusion proteins; Sulfasalazine; Treatment; Tumor necrosis factor alpha

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; CANAKINUMAB; CERTOLIZUMAB PEGOL; CYCLOSPORIN; ETANERCEPT; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; INTERLEUKIN 1 INHIBITOR; LEFLUNOMIDE; MELOXICAM; METHOTREXATE; NAPROXEN; PENICILLAMINE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; RITUXIMAB; SALAZOSULFAPYRIDINE; STEROID; TACROLIMUS; THALIDOMIDE; TOCILIZUMAB; TOFACITINIB; TRIAMCINOLONE ACETONIDE; TRIAMCINOLONE HEXACETONIDE; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; AMINOTRANSFERASE BLOOD LEVEL; ARTHRITIS; ARTICLE; BIOLOGICAL THERAPY; CATARACT; COMPARATIVE EFFECTIVENESS; CYTOPENIA; DRUG ANTAGONISM; DRUG CHOICE; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GROWTH INHIBITION; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; INFUSION RELATED REACTION; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; LIVER TOXICITY; METABOLISM; MOOD DISORDER; MOUTH ULCER; NAUSEA; NEUTROPENIA; OSTEOPOROSIS; POLYARTICULAR ARTHRITIS; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; BIOLOGICAL THERAPY; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-1; INTERLEUKIN-6; METHOTREXATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84881165567     PISSN: 15297322     EISSN: 15346315     Source Type: Journal    
DOI: 10.1007/s11882-013-0351-2     Document Type: Article

References (73)

1. Petty R, Southwood T, Manners P, et al. International League of Associations for Rheumatology classifications of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390-2.
2. Helmick C, Felson D, Lawrence R, et al. National Arthritis Data Workgroup: Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58:15-25.
3. Giannini E, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40:1202-9.
4. Woodrick RS, Ruderman EM. Safety of biologic therapy in rheumatoid arthritis. Nat Rev Rheumatol. 2011;7:639-52.
5. •• Beukelman T, Patkar NM, Saag KG, et al. American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Initiation and Safety Monitoring of Therapeutic Agents for the Treatment of Arthritis and Systemic Features. Arthritis Care Res. 2011;63:465-82. This article summarizes the American College of Rheumatology treatment recommendations for juvenile idiopathic arthritis.
6. Ruperto N, Nikishina I, Pachanov ED, et al. A Randomized, Double-Blind Clinical Trial of Two Doses of Meloxicam Compared With Naproxen in Children With Juvenile Idiopathic Arthritis. Arthritis Rheum. 2005;52:563-72.
7. Dowd JE, Cimaz R, Fink CW. Nonsteroidal anti-inflammatory drug-induced gastroduodenal injury in children. Arthritis Rheum. 1995;38:1225-31.
8. Ardoin SP, Sundy JS. Update on nonsteroidal anti-inflammatory drugs. Curr Opin Rheumatol. 2006;18:221-6.
9. Vora SS, Bengtson CE, Syverson GD, Nocton JJ. An evaluation of the utility of routine laboratory monitoring of juvenile idiopathic arthritis (JIA) patients using non-steroidal anti-inflammatory drugs (NSAIDs): a retrospective review. Pediatr Rheumatol Online J. 2010;8:11.
10. Padeh S, Passwell JH. Intraarticular corticosteroid injection in the management of children with chronic arthritis. Arthritis Rheum. 1998;41:1210-4.
11. Marti P, Molinari L, Bolt IB, Seger R, Saurenmann RK. Factors Influencing the efficacy of intra-articular steroid injections in patients with juvenile idiopathic arthritis. Eur J Pediatr. 2008;167:425-30.
12. Zulian F, Martini G, Gobber D, et al. Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial. Rheumatology. 2004;43:1288-91.
13. Goldzweig O, Carrasco R, Hashkes PJ: Systemic adverse events following intraarticular corticosteroid injections for the treatment of juvenile idiopathic arthritis: Two patients with dermatologic adverse events and review of the literature. Semin Arthritis Rheu 2012, In press.
14. Ilowite NT, Laxer RM. Pharmacology and Drug Therapy. In: Cassidy JT, Petty RE, Laxer RM, Lindsley CB, editors. Textbook of Pediatric Rheumatology. 6th ed. Philadelphia: Saunders Elsevier; 2011. p. 71-126.
15. Schaller JG. Corticosteroids in juvenile rheumatoid arthritis. Arthritis Rheum. 1977;20:537-43.
16. •• Dewitt EM, Kimura Y, Beukelman T, et al. Consensus Treatment Plans for New-Onset Systemic Juvenile Idiopathic Arthritis. Arthrit Care Res. 2012;64:1001-10. This article summarizes consensus treatment plans from the Childhood Arthritis and Rheumatology Research Alliance for new-onset systemic juvenile idiopathic arthritis.
17. Ilowite NT, Sandborg CI, Feldman BM, et al. Algorithm development for corticosteroid management in systemic juvenile idiopathic arthritis trial using consensus methodology. Pediatr Rheumatol Online J. 2012;10:31.
18. Prieur AM. The place of corticosteroid therapy in juvenile chronic arthritis in 1992. J Rheumatol. 1993;37:32-4.
19. Wallace CA, Giannini EH, Spalding SJ, et al. Trial of Early Aggressive Therapy in Polyarticular Juvenile Idiopathic Arthritis. Arthritis Rheum. 2012;64:2012-21.
20. Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate in Resistant Juvenile Rheumatoid Arthritis. Results of the U.S.A.-U.S.S.R. Double-Blind, Placebo-Controlled Trial. N Engl J Med. 1992;326:1043-9.
21. Woo P, Southwood TR, Prieur A-M, et al. Randomized, Placebo-Controlled, Crossover Trial of Low-Dose Oral Methotrexate in Children with Extended Oligoarticular or Systemic Arthritis. Arthritis Rheum. 2000;43:1849-57.
22. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. Arthritis Rheum. 2008;59:762-84.
23. Silverman E, Mouy R, Spiegel L, et al. Leflunomide or Methotrexate for Juvenile Rheumatoid Arthritis. N Engl J Med. 2005;352:1655-66.
24. Silverman E, Spiegel L, Hawkins D, et al. Long-Term Open-Label Preliminary Study of the Safety and Efficacy of Leflunomide in Patients With Polyarticular-Course Juvenile Rheumatoid Arthritis. Arthritis Rheum. 2005;52:554-62.
25. Burgos-Vargas R, Vazquez-Mellado J, Pacheco-Tena C, et al. A 26 week randomized, double blind, placebo controlled exploratory study of sulfasalazine in juvenile onset spondyloarthropathies. Ann Rheum Dis. 2002;61:941-2.
26. Van Rossum MAJ, Fiselier TJW, Franssen MJAM, et al. Sulfasalazine in the Treatment of Juvenile Chronic Arthritis. Arthritis Rheum. 1998;41:808-16.
27. Van Rossum MAJ, van Soesbergen RM, Boers M, et al. Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. Ann Rheum Dis. 2007;66:1518-24.
28. Savolainen HA, Kautiainen H, Isomäki H, et al. Azathioprine in patients with juvenile chronic arthritis: a longterm followup study. J Rheumotol. 1997;24:2444-50.
29. Lin YT, Yang YH, Tsai MJ, Chiang BL. Long-term effects of azathioprine therapy for juvenile idiopathic arthritis. J Formos Med Assoc. 2000;99:330-5.
30. Ruperto N, Ravelli A, Castell E, et al. Cyclosporine A in juvenile idiopathic arthritis. Results of the PRCSG/PRINTO phase IV post marketing surveillance study. Clin Exp Rheumatol. 2006;24:599-605.
31. Brewer EJ, Giannini EH, Kuzmina N, Alekseev L. Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis. N Engl J Med. 1986;314:1269-76.
32. Kvien TK, Høyeraal HM, Sanstad B. Slow Acting Antirheumatic Drugs in Patients with Juvenile Rheumatoid Arthritis - Evaluated in a Randomized, Parallel 50-Week Clinical Trial. J Rheumatol. 1985;12:533-9.
33. Tanaka H, Tsugawa K, Suzuki K, et al. Treatment of difficult cases of systemic-onset juvenile idiopathic arthritis with tacrolimus. Eur J Pediatr. 2007;166:1053-5.
34. Lehman TJ, Schechter SJ, Sundel RP, et al. Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study. J Pediatr. 2004;145:856-7.
35. Garcia-Carrasco M, Fuentes-Alexandro S, Escárcega RO, et al. Efficacy of thalidomide in systemic onset juvenile rheumatoid arthritis. Joint Bone Spine. 2007;74:500-3.
36. Shenoi S, Wallace CE. Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review. Paediatr Drugs. 2010;12:367-77.
37. Alonso-Ruiz A, Pijoan JI, Ansuategui E, et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord. 2008;9:52.
38. Tynjälä P, Vähäsalo P, Tarkiainen M, et al. Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis (ACUTE-JIA): a multicenter randomized open-label clinical trial. Ann Rheum Dis. 2011;70:1605-12.
39. Singh JA, Furst DE, Bharat A, et al. Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis. Arthrit Care Res. 2012;2012(64):625-39.
40. U.S. Food and Drug Administration: FDA: Cancer Warnings Required for TNF Blockers. Available at www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm175803.htm. Accessed January 2013.
41. Beukelman T, Haynes K, Curtis JR, et al. Rates of Malignancy Associated With Juvenile Idiopathic Arthritis and Its Treatment. Arthritis Rheum. 2012;64:1263-71.
42. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in Children with Polyarticular Juvenile Rheumatoid Arthritis. N Engl J Med. 2000;342:763-9.
43. Giannini EH, Ilowite NT, Lovell DJ, et al. Long-Term Safety and Effectiveness of Etanercept in Children With Selected Categories of Juvenile Idiopathic Arthritis. Arthritis Rheum. 2009;60:2794-804.
44. Otten MH, Prince FHM, Armbrust W, et al. Factors Associated With Treatment Response to Etanercept in Juvenile Idiopathic Arthritis. JAMA. 2011;306:2340-7.
45. Bracaglia C, Buonuomo PS, Tozzi AE, et al. Safety and Efficacy of Etanercept in a Cohort of Patients with Juvenile Idiopathic Arthritis Under 4 Years of Age. J Rheumatol. 2012;39:1287-90.
46. Ruperto N, Lovell DJ, Cuttica R, et al. A Randomized, Placebo-Controlled Trial of Infliximab Plus Methotrexate for the Treatment of Polyarticular-Course Juvenile Rheumatoid Arthritis. Arthritis Rheum. 2007;56:3096-106.
47. Ruperto N, Lovell DJ, Cuttica R, et al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis. 2010;69:718-22.
48. Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis. N Engl J Med. 2008;359:810-20.
49. Ruiz Garcia V, Jobanputra P, Burls A, et al. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database Syst Rev. 2011;2, CD007649.
50. Singh JA, Noorbaloochi S, Singh G. Golimumab for Rheumatoid Arthritis: A Systematic Review. J Rheumatol. 2010;37:1096-104.
51. Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372:383-91.
52. Ruperto N, Lovell DJ, Li T, et al. Abatacept Improves Health-Related Quality of Life, Pain, Sleep Quality, and Daily Participation in Subjects With Juvenile Idiopathic Arthritis. Arthritis Care Res. 2010;62:1542-51.
53. Ruperto N, Lovell DJ, Quartier P, et al. Long-term Safety and Efficacy of Abatacept in Children with Juvenile Idiopathic Arthritis. Arthritis Rheum. 2010;62:1792-802.
54. Moltó A, Olivé A. Anti-Il-1 molecules: new comers and new indicators. Joint Bone Spine. 2010;77:102-7.
55. Reddy S, Jia S, Geoffrey R, et al. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N Engl J Med. 2009;360:2438-44.
56. Aksentijevich I, Masters SL, Ferguson PJ, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med. 2009;360:2426-37.
57. Ilowite N, Porras O, Reiff A, et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol. 2009;28:129-37.
58. Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70:747-54.
59. Nigrovic PA, Mannion M, Prince FHM, et al. Anakinra as First-Line Disease-Modifying Therapy in Systemic Juvenile Idiopathic Arthritis. Arthritis Rheum. 2011;63:545-55.
60. Ruperto N, Quartier P, Wulffraat M, et al. A Phase II, Multicenter, Open-Label Study Evaluating Dosing and Preliminary Safety and Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis With Active Systemic Features. Arthritis Rheum. 2012;64:557-67.
61. • Ruperto N, Brunner HI, Quartier P, et al. Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis. N Engl J Med. 2012;367:2396-406. This article discusses two trials of canakinumab, a new IL-1 inhibitor, for treatment in systemic juvenile idiopathic arthritis.
62. Lovell DJ, Giannini EH, Kimura Y, et al. Preliminary evidence for sustained bioactivity of IL-1 trap (rilonacept), a long acting IL-1 inhibitor, in systemic juvenile idiopathic arthritis (SJIA). Arthritis Rheum. 2007;56:S515.
63. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Randomized Placebo Phase Study of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis (RAPPORT). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2013 Jan 30]. Available from: http://clinicaltrials.gov/ct2/show/NCT00534495 NLM Identifier: NCT00534495.
64. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998-1006.
65. Yokota S, Imagawa T, Mori M, et al. Long-term treatment of systemic juvenile idiopathic arthritis with tocilizumab: results of an open-label extension study in Japan. Ann Rheum Dis. 2012;0:1-2.
66. • De Benedetti F, Brunner HI, Ruperto N, et al. Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis. N Engl J Med. 2012;367:2385-95. This article discusses a randomized trial of tocilizumab, an IL-6 inhibitor, which demonstrated a significant improvement in treatment of systemic juvenile idiopathic arthritis in the tocilizumab group compared to the placebo group.
67. U.S. Food and Drug Administration: FDA Approves Xeljanz for rheumatoid arthritis. Available at http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm327152.htm. Accessed January 2013.
68. LaBranche TP, Jesson MI, Radi ZA, et al. JAK Inhibition With Tofacitinib Suppresses Arthritis Joint Structural Damage Through Decreased RANKL Production. Arthritis Rheum. 2012;64:3531-42.
69. Fleischmann R, Kremer J, Cush J, et al. Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis. N Engl J Med. 2012;367:495-507.
70. Pfizer. An Open-Label Multiple Dose Study To Evaluate The Pharmacokinetics, Safety and Tolerability Of CP-690,550 In Pediatric Patients From 2 To Less Than 18 Years Of Age With Juvenile Idiopathic Arthritis (JIA). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2013 Jan 30]. Available from: http://clinicaltrials.gov/ct2/ show/NCT01513902 NLM Identifier: NCT01513902.
71. Pfizer. A Long-Term, Open-Label Follow-Up Study Of CP-690,550 For Treatment Of Juvenile Idiopathic Arthritis (JIA). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2013 Jan 30]. Available from: http://clinicaltrials.gov/ct2/show/NCT01500551 NLM Identifier: NCT01500551.
72. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for Rheumatoid Arthritis Refractory to Anti-Tumor Necrosis Factor Therapy. Arthritis Rheum. 2006;54:2793-806.
73. Alexeeva EI, Valieva SI, Bzarova TM, et al. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin Rheumatol. 2011;30:1163-72.